Outlook Therapeutics Inc (NASDAQ:OTLK)

2.18
Delayed Data
As of Oct 22
 +0.07 / +3.32%
Today’s Change
0.72
Today|||52-Week Range
4.26
+67.69%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$371.7M

Company Description

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification, development, manufacture, and commercialization of ONS-5010/LYTENAVA as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Contact Information

Outlook Therapeutics, Inc.
485 Route 1 South
Iselin New Jersey 08830
P:(609) 619-3990
Investor Relations:

Employees

Shareholders

Mutual fund holders6.23%
Other institutional5.68%
Individual stakeholders47.34%

Top Executives

C. Russell TrenaryPresident, Chief Executive Officer & Director
Terry DagnonChief Operating Officer
Lawrence A. KenyonCFO, Secretary, Treasurer & Director
Jennifer M. KissnerSenior Vice President-Clinical Development
Jeff EvansonChief Commercial Officer